GENE ONLINE|News &
Opinion
Blog

2021-07-30| M&A

PerkinElmer Makes its Biggest Buy Yet Forking Out $5.25 Billion for Latest Acquisition

by Rajaneesh K. Gopinath
Share To

PerkinElmer is on a hot streak, buying several companies in the past nine months. Since snagging Horizon Discovery for $383 million last November, the firm has acquired five more so far.

With the acquisition of Oxford Immunotec Global PLC for $591 million, PerkinElmer has had a solid start to 2021, entering the tuberculosis diagnostic market. Soon after, it picked up Nexcelom Bioscience for $260 million and Immunodiagnostic Systems Holdings PLC for $155 million.

In June, the company announced plans to further broaden its existing cell and gene research solutions by adding viral vector gene delivery leader SIRION Biotech GmbH to its buying spree. Just a month later, the Waltham, MA-based company, has now announced its biggest acquisition yet.

 

$5.25 Billion Acquisition

On July 26th, PerkinElmer entered into an agreement to acquire San Diego-based BioLegend in a cash and stock deal worth approximately $5.25 billion. BioLegend is a leading global provider of life science antibodies and reagents. With this massive acquisition, PerkinElmer is looking to establish itself as a leader in the market.

The company also announced its revenue for the second quarter of 2021, a whopping $1.228 billion as compared to the $812 million it made in the second quarter of 2020. In addition, its share, which stood at $74.80 in March 2020, has grown steadily to an all-time high of $182.23. The new acquisition will put PerkinElmer in a much better position to emulate these numbers.

“We are thrilled to have the opportunity to bring our technologies and innovative cultures together to create seamless solutions to push science and discovery forward. We believe joining our teams presents an incredible opportunity to accelerate discoveries that help life science researchers leverage ever-developing technologies and novel approaches to better understand and fight disease,” said Prahlad Singh, President, and CEO of PerkinElmer.

 

Opportunity for Growth

“We are very excited to join the PerkinElmer family. The combination will afford us the opportunity to continue to build on our two-decade foundation of innovative science and scale in new and highly attractive PerkinElmer areas such as clinical diagnostics and food safety testing. The BioLegend team is eager to enter this new chapter with PerkinElmer, furthering our mission of enabling legendary discovery from research to cure,” said Gene Lay, Founder, President, and CEO of BioLegend.

BioLegend, founded in 2002 by Gene Lay, has grown into a company with more than 700 employees. The privately held company provides cutting-edge antibodies and reagents for biomedical research encompassing therapeutic areas such as Immunology, Neuroscience, Cancer, Stem cells, and Clinical Products. It is estimated to bring in $380 million in revenue in 2022.

Upon acquisition, BioLegend will expand PerkinElmer’s existing life science franchise into new segments, an official statement read. BioLegend’s state-of-the-art campus in San Diego will become PerkinElmer’s global Center of Excellence (CoE) for research reagent content development for the combined company. The acquisition is expected to close by the end of this year.

Related Article: Amgen Acquires Teneobio to Snag New Class of Antibody Therapies

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
PerkinElmer Sells Three of its Businesses for $2.45 Billion
2022-08-03
IPO
Could this Biotech be the First Billion-Dollar Hong Kong Startup to Go Public?
2021-07-18
M&A
Why is PerkinElmer Buying Horizon Discovery?
2020-11-02
LATEST
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
Scientists Identify New Genetic Variant Related to Obesity
2022-12-01
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
FDA Revokes Authorization Of Eli Lilly’s COVID-19 Antibody
2022-12-01
Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
2022-11-30
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
2022-11-30
Gland Pharma Dispels Rumors Of Fosun Sale, Acquires Cenexi In Separate Development
2022-11-30
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!